Satellos Bioscience Inc T.MSCL

Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by db2067on Nov 25, 2021 10:10pm

210 Views

Post# 34167339

U of T Gilbert lab

U of T Gilbert lab: Development of a personalized in-vitro model for dystrophic muscle endogenous repair for drug discovery https://www.mitacs.ca/en/projects/development-personalized-vitro-model-dystrophic-muscle-endogenous-repair-drug-discovery

Satellos Bioscience Inc is developing small molecule drugs that target and modulate DMD muscle stem cells to repair the dystrophic muscle. --- This project aims to develop a feasible model to bridge the gap between animal experiments and human clinical trials and enable Satellos to identify drug candidates most likely to ultimately succeed in clinical trials.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project